Phenotyping and Target Expression Profiling of CD34+ /CD38- and CD34+ /CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia

Neoplasia : an International Journal for Oncology Research
Katharina BlattPeter Valent

Abstract

Leukemic stem cells (LSCs) are an emerging target of curative anti-leukemia therapy. In acute lymphoblastic leukemia (ALL), LSCs frequently express CD34 and often lack CD38. However, little is known about markers and targets expressed in ALL LSCs. We have examined marker- and target expression profiles in CD34+/CD38- LSCs in patients with Ph+ ALL (n = 22) and Ph- ALL (n = 27) by multi-color flow cytometry and qPCR. ALL LSCs expressed CD19 (B4), CD44 (Pgp-1), CD123 (IL-3RA), and CD184 (CXCR4) in all patients tested. Moreover, in various subgroups of patients, LSCs also displayed CD20 (MS4A1) (10/41 = 24%), CD22 (12/20 = 60%), CD33 (Siglec-3) (20/48 = 42%), CD52 (CAMPATH-1) (17/40 = 43%), IL-1RAP (13/29 = 45%), and/or CD135 (FLT3) (4/20 = 20%). CD25 (IL-2RA) and CD26 (DPPIV) were expressed on LSCs in Ph+ ALL exhibiting BCR/ABL1p210, whereas in Ph+ ALL with BCR/ABL1p190, LSCs variably expressed CD25 but did not express CD26. In Ph- ALL, CD34+/CD38- LSCs expressed IL-1RAP in 6/18 patients (33%), but did not express CD25 or CD26. Normal stem cells stained negative for CD25, CD26 and IL-1RAP, and expressed only low amounts of CD52. In xenotransplantation experiments, CD34+/CD38- and CD34+/CD38+ cells engrafted NSG mice after 12-20 we...Continue Reading

Citations

Jul 6, 2019·Médecine sciences : M/S·Mathieu Neto Da RochaChristophe Ferrand
Jul 15, 2018·Wiener klinische Wochenschrift·Peter ValentChristoph Zielinski
Sep 1, 2019·International Journal of Molecular Sciences·Peter ValentDominik Wolf
Nov 12, 2019·Frontiers in Oncology·Massimiliano BonifacioFrancesco Di Raimondo
Sep 17, 2019·World Journal of Stem Cells·Mohammad HoushmandMahin Nikougoftar Zarif
Jun 16, 2021·Hematology, Transfusion and Cell Therapy·Míriam P BeltrameMaura R V Ikoma-Colturato

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
flow cytometry

Key Resources (RRID) Mentioned

CVCL_2106

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.